Clinical trials: COVID-19; Immunity
Chronic Kidney Diseases, COVID-19
Observation of the Immune Response After COVID-19 Additional Vaccine Doses in Chronic Patients in Hemodialysis Therapy
Observation of humoral and cellular immune response after additional dose vaccine with different COVID-19 vaccines in ESKD patients in hemodialysis therapy.
- Conditions
- Chronic Kidney Diseases, COVID-19, Hemodialysis
- Trial name
- COVID-thIRd (NCT05142501)
- Testing
- Blood samples
- Where
- 11 sites in Portugal, Spain
- Volunteers
- 23 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Relapsing Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab
This study aimed to understand whether patients with relapsing multiple sclerosis (RMS) can mount an immune response to SARS-CoV-2 mRNA vaccines (initial vaccinations or booster vaccines) when vaccinated either before initiation…
- Trial name
- KYRIOS (NCT04869358)
- Testing
- Ofatumumab
- Where
- 6 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19
The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines
Clinical trial with randomized allocation in two arms (BCG vaccine versus placebo) of volunteers at risk but not yet infected nor vaccinated against SARS-CoV-2.
- Trial name
- SARS-CoV-2 (NCT05507671)
- Testing
- BCG (Bacillus Calmette-Guérin) vaccine
- Where
- 4 sites in Brazil
- Volunteers
- 556 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
Hematologic Diseases
Evaluation of the Immune Response to Sars-Covid-19 Vaccines in Haematological Patients: Prospective Single Center Study
The main objective of this study is to investigate the humoral immune response to COVID-19 vaccines in haematological patients, by testing SARS-CoV-2 seroconversion
- Trial name
- Hema-C19-Vax (NCT05074706)
- Testing
- IgG antibodies to Sars-Cov-2, QuantiFERON SARS-CoV-2 test
- Where
- Italy
- Volunteers
- 700 people
- Sponsor
- University of Milano Bicocca
COVID-19, SARS-CoV-2
Professional's Health in Epidemiological Crisis Covid-19
Introduction: Coronavirus Disease 2019 (COVID-19) has caused a global pandemic. Epidemiological and clinical inter-individual differences, symptomatology, recovery and humoral response against Severe Acute Respiratory Syndrome…
- Trial name
- ProHEpiC-19 (NCT04885478)
- Testing
- Immune response monitoring , blood samples
- Where
- Spain
- Volunteers
- 1,350 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Corona Virus Infection
Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection
The SARS-CoV-2 (COVID-19) infection is causing a global pandemic and a major health crisis in France. Immunity is the body's ability to defend itself against infectious agents such as viruses.
- Trial name
- ImmuCoV (NCT04707820)
- Testing
- ELISPOT
- Where
- France
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- University Hospital, Rouen
COVID-19, Immunologic Factors
Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine.
A two-stage trial will involve healthy volunteers. The first stage is open trial, and the second stage is a double-blind trial with randomization of volunteers into three groups.
- Conditions
- COVID-19, Immunologic Factors, Coronavirus Infections, Respiratory Tract Infections
- Trial name
- NCT05156723
- Testing
- Subunit recombinant vaccine for the prevention of coronavirus infection
- Where
- 3 sites in Russia
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
COVID-19, SARS-CoV-2 Infection
Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins in COVID-19 Patients
SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has negatively impacted global health and requires more research to develop better tests and to improve disease treatment.
- Trial name
- SARS-CoV-2 (NCT04465981)
- Testing
- Sampling
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- INanoBio Inc.
Covid19, Immune Suppression
Differences in Immune Response Among HIV-1-infected Individuals With Previous or Current COVID-19 (CoVIHDis).
People living with HIV could have different susceptibility and outcome to the SARS CoV-2 infection. The risk of SARS CoV-2 infection in this population could be no related to HIV infection, immunodepression or antiretroviral…
- Conditions
- Covid19, Immune Suppression, HIV-1-infection
- Trial name
- CoVIHDis (NCT04526977)
- Testing
- Immune response study
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Asociacion para el Estudio de las Enfermedades Infecciosas
COVID-19
Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans
Background: The higher death rate from COVID-19 in the older population is associated with low CD8 T cell counts in the blood. Researchers want to learn the status of CD8 T cells specific to SARS-CoV-2 and their changes with…
- Trial name
- NCT04565067
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Institute on Aging (NIA)
Sars-CoV2
Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff
COVID-19 is a pathology linked to the SARS-CoV-2 virus, a new virus of the coronaviridae family that emerged in China in December 2019 before rapidly becoming a pandemic according to the WHO on March 11, 2020.
- Trial name
- IMMUNO-COVID (NCT04408001)
- Testing
- Clinical interview, Blood collection, Saliva collection
- Where
- France
- Volunteers
- 499 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
SARS-CoV-2
Prognostic Factors of COVID19
COVID-19 is an emerging disease, for which no specific treatment options are currently available. Since the end of February 2020, and due to a SARS-CoV-2 superspreading event (religious meeting), the Strasbourg University…
- Trial name
- Covid-HUS (NCT04405726)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Strasbourg, France
Apnea, Obstructive Sleep, SARS CoV 2 Infection
Impact of Sleep Disorders on Innate Immunity in COVID-19 Patients
Sleep is an important modulator of the immune response, whereby sleep disturbances (ie, poor sleep quality, insufficient sleep and/or primary sleep disorder, obstructive sleep apnea (OSA)) contribute to inflammatory disease risk…
- Trial name
- NCT06341374
- Testing
- Influvac Tetra
- Where
- Spain
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Parc Taulí Hospital Universitari
Covid19
Estimation of Dynamics of Humoral and Cellular Immunity in COVID-19 Patients
The goal of the project: to study the dynamics of the humoral and cellular immunity in patients after pneumonia caused by the SARS-CoV-2 virus at different time intervals, in order to predict the duration of immune protection
- Trial name
- NCT04649840
- Testing
- Humoral and cellular immunity
- Where
- Belarus
- Volunteers
- 274 people
- Sponsor
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Kidney Failure, Chronic, Covid19
Assessment of Immune Response After Vaccination Against COVID-19 in Patients Treated With Renal Replacement Therapy
Chronically dialyzed patients and kidney transplant recipients have been identified as particularly vulnerable to SARS-CoV-2 infection due to unavoidable exposure.
- Conditions
- Kidney Failure, Chronic, Covid19, Vaccine Reaction, Vaccine Adverse Reaction
- Trial name
- COViNEPH-1 (NCT04905862)
- Testing
- Immune response, Solicited common and expected adverse reactions shortly following vaccination (reactogenicity), use of antipyretic or pain medications and unsolicited adverse events and serious adverse events
- Where
- 4 sites in Poland
- Volunteers
- 180 people
- Sponsor
- Medical University of Gdansk
SARS-CoV-2, COVID-19
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults.
- Trial name
- NCT05960097
- Testing
- CV0701 mRNA COVID-19 Vaccine (Low dose), CV0701 mRNA COVID-19 Vaccine (Medium dose), CV0701 mRNA COVID-19 Vaccine (High dose)
- Where
- 17 sites in United States, Australia
- Volunteers
- 692 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis, Covid19
Estimating Prevalence of COVID-19 Infection and SARS-CoV-2 Antibodies in MS Patients
This non-interventional, biospecimen collection study is designed to help us better understand whether MS patients have impaired immune defenses to COVID-19 infection.
- Trial name
- NCT04682548
- Where
- United States
- Volunteers
- 920 people
- Sponsor
- NYU Langone Health
Covid19
Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial
This pilot double-blind randomized controlled trial will test the preliminary efficacy of two doses of a combination of live microbials (probiotics) given to boost the immunity of unvaccinated persons previously infected with…
- Trial name
- NCT04847349
- Testing
- OL-1, standard dose, OL-1, high dose
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
COVID-19, Vaccine Immune Response
COVID-19 Vaccine Reactogenicity and Immunogenicity
Analysis of antibody kinetics after vaccination with mRNA-1273 and factors influencing the vaccine immunogenicity
- Conditions
- COVID-19, Vaccine Immune Response, Vaccine Adverse Reaction
- Trial name
- NCT05258708
- Testing
- mRNA-1273 COVID-19 vaccine
- Where
- 5 sites in South Korea
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
SARS-CoV Infection, Covid19
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants.
- Trial name
- NCT04611802
- Testing
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)
- Where
- 154 sites in United States, Mexico and 1 more
- Volunteers
- 33,000 people, healthy volunteers welcome
- Sponsor
- Novavax